{"organizations": [], "uuid": "3e320b3897a8a049107111c347107325599a5a74", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-catabasis-pharma-aligns-resources/brief-catabasis-pharma-aligns-resources-to-focus-on-lead-program-edasalonexent-idUSFWN1RU19I", "country": "US", "domain_rank": 408, "title": "BRIEF-Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T23:06:00.000+03:00", "replies_count": 0, "uuid": "3e320b3897a8a049107111c347107325599a5a74"}, "author": "", "url": "https://www.reuters.com/article/brief-catabasis-pharma-aligns-resources/brief-catabasis-pharma-aligns-resources-to-focus-on-lead-program-edasalonexent-idUSFWN1RU19I", "ord_in_thread": 0, "title": "BRIEF-Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "lead program edasalonexent reuters", "sentiment": "none"}, {"name": "catabasis pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17, 2018 / 8:09 PM / Updated 11 minutes ago BRIEF-Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent Reuters Staff 1 Min Read \nApril 17 (Reuters) - Catabasis Pharmaceuticals Inc: \n* CATABASIS PHARMACEUTICALS ALIGNS RESOURCES TO FOCUS ON LEAD PROGRAM EDASALONEXENT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY \n* CATABASIS PHARMACEUTICALS INC - STRATEGIC CORPORATE RESTRUCTURING SUPPORTS GOAL OF ADVANCING EDASALONEXENT TOWARDS POTENTIAL REGISTRATION \n* CATABASIS PHARMACEUTICALS INC - RESTRUCTURING WILL REDUCE COMPANYâ€™S WORKFORCE BY APPROXIMATELY 42% \n* CATABASIS PHARMACEUTICALS INC - ESTIMATES ANNUALIZED SAVINGS OF APPROXIMATELY $3.3 MILLION IN PERSONNEL-RELATED COSTS \n* CATABASIS PHARMACEUTICALS INC - ESTIMATED ONE-TIME SEVERANCE AND RELATED COSTS OF APPROXIMATELY $1.0 MILLION IN Q2 OF 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-17T23:06:00.000+03:00", "crawled": "2018-04-17T23:22:32.003+03:00", "highlightTitle": ""}